- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03365687
Vitamin D In the Prevention of Viral-induced Asthma in Preschoolers (DIVA)
Vitamin D In the Prevention of Viral-induced Asthma in Preschoolers: a Randomized Controlled Multicenter Trial (DIVA)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a multicenter triple-blind randomized parallel-group, placebo-controlled trial of vitamin D3 supplementation. Children aged 1-5 (<6) years with physician-diagnosed asthma predominantly triggered by upper respiratory tract infection will be screened for enrolment in paediatric asthma, respiratory or allergy clinics and the ED departments and randomized between Sept 1 to January 31, annually (4 recruitment years).
Using a computer-generated random list, stratified by site, children will be allocated (1:1) using permuted block randomisation method to enhance concealment.
Children will be followed for 7 months, with 3 visits every 3.5 months with repeated urine (for calcium:creatinine ratio) and blood samples. In addition, ten (10) days after each bolus, urine will be sampled for urinary calcium:creatinine ratio. In case of elevated urine calcium:creatinine ratio, a blood sample may be needed primarily for markers of calcium metabolism and exploratory outcomes. Only patients enrolled at CHU Sainte-Justine and Montreal Children's Hospital will receive a systematic home visit 10 days after first bolus for both urine and blood samples. There will be 6 follow-up phone calls, at week 1 and then monthly, to inquire about exacerbations and URTIs, remind parents to complete questionnaires and to collect a nasal swab at each exacerbation and screen for adverse events.
The main outcome is the number of courses of rescue oral corticosteroids (OCS) per child during the study period. Several secondary outcomes will be documented using biological samples and validated questionnaires to ascertain laboratory-confirmed respiratory infections, intensity and severity of exacerbations, mean number of ED visits, parents' functional status during exacerbations, de-intensification of preventive asthma therapy, cost effectiveness, and safety profile.
A sample of 432 children (400+7,5% attrition) per arm will provide 80% power with a two-tailed alpha of 5% to detect a 25% relative reduction in the mean number of exacerbations requiring OCS per child.
An intention-to-treat (ITT) analysis will be carried out with all randomised children.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Francine M Ducharme, MD
- Phone Number: 4398 514-345-4931
- Email: francine.m.ducharme@umontreal.ca
Study Contact Backup
- Name: Andrea Laszlo
- Phone Number: 7243 514-345-4931
- Email: andrea.laszlo.hsj@ssss.gouv.qc.ca
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6H 3V4
- Recruiting
- British Columbia Children's Hospital
-
Contact:
- Connie Yang, MD
- Phone Number: 4931 1-6048752000
- Email: connie.yang@cw.bc.ca
-
Principal Investigator:
- Connie Yang, MD
-
-
Ontario
-
London, Ontario, Canada, N6A 2V5
- Recruiting
- Children's Hospital of London Health Sciences Centre
-
Contact:
- Dirk Bock, MD
- Phone Number: 1-5196858824
- Email: Dirk.Bock@lhsc.on.ca
-
Principal Investigator:
- Dirk Bock, MD
-
Ottawa, Ontario, Canada, K1H 8L1
- Recruiting
- Children's Hospital of Eastern Ontario
-
Contact:
- Dhenuka Radhakrishnan, MD
- Phone Number: 2868 1-6137377600
- Email: dradhakrishnan@cheo.on.ca
-
Principal Investigator:
- Dhenuka Radhakrishnan, MD
-
Toronto, Ontario, Canada, M5G 1X8
- Recruiting
- The Hospital For Sick Children
-
Contact:
- Lucy Perrem, MD
- Phone Number: 328077 416-813-7654
- Email: Lucy.Perrem@sickkids.ca
-
-
Quebec
-
Montreal, Quebec, Canada, H3H 1P3
- Recruiting
- Montreal Children's Hospital
-
Contact:
- Reza Alizadehfar, MD
- Email: reza.alizadehfar@muhc.mcgill.ca
-
Contact:
- Duncan Lejtenyi, MSc
- Phone Number: 22369 1-514-412-4400
- Email: duncan.lejtenyi@muhc.mcgill.ca
-
Principal Investigator:
- Reza Alizadehfar, MD
-
Montreal, Quebec, Canada, H3T1C5
- Recruiting
- CHU Sainte Justine
-
Contact:
- Sze Man Tse
- Phone Number: 54 514-345-4931
- Email: sze.man.tse@umontreal.ca
-
Principal Investigator:
- Sze Man Tse
-
Montreal, Quebec, Canada
- Recruiting
- Maisonneuve-Rosemont Hospital
-
Contact:
- Marc-Andre Turcot, MD
- Email: marc-andre.turcot@umontreal.ca
-
Principal Investigator:
- Marc-Andre Turcot
-
Québec, Quebec, Canada, G1V 4G2
- Recruiting
- CHU de Quebec-Universite Laval
-
Contact:
- Patrick Daigneault, MD
- Email: Patrick.Daigneault@mail.chuq.qc.ca
-
Contact:
- Louise Gosselin
- Phone Number: 48290 418-525-4444
- Email: louise.gosselin@chudequebec.ca
-
Principal Investigator:
- Patrick Daigneault, MD
-
Sherbrooke, Quebec, Canada, J1G 2E8
- Active, not recruiting
- CHU de Sherbrooke
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 1-5 years
- Physician-diagnosed asthma (as per the 2015 Canadian Position Paper on the diagnosis of preschool asthma)
- ≥1 asthma exacerbation requiring rescue oral corticosteroids (OCS) in the past 6 months or ≥2 in the past 12 months (as documented by pharmacy/medical records)
- ≥4 upper respiratory tract infections (URTIs) in the past 12 months (as per parental report)
- URTIs as the main asthma trigger (as per parental report)
Exclusion Criteria:
- Intake > 400 IU/day of vitamin D3 supplements or fish oil in the past 3 months
- Intention to use > 400 IU/day of vitamin D3 supplements or fish oil in the fall and winter
- Extreme prematurity (< 28 week gestation)
- No vitamin D supplementation (if breast-fed in the last 6 months)
- Vitamin D restrictive diets, that is, minimal intake of vitamin D fortified milk (<250 mL/day for 1-3 years or <375 mL/day for 4-6 years AND no other (or <200 IU/day) vitamin D supplement
- Recent immigrants from regions at high risk of rickets (in the past 12 months)
- Recent refugees (in the past 12 months)
- Undernourished children
- Other chronic respiratory disease (e.g. Cystic fibrosis, Bronchopulmonary dysplasia) or chronic kidney, gastrointestinal, endocrinological or cardiac diseases, or sickle cell anemia?
- History of bone disorder disease (e.g. rickets, osteomalacia)
- Intake of oral anti-epileptic, diuretic or anti-fungal medications
- Anticipated difficulty with follow-up or with adherence to the intervention or the procedures
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Vitamin D
Vitamin D supplement (100,000 IU) orally at baseline and at 3.5 months with daily 400 IU vitamin D for 7 months
|
2 mL of 50,000 IU/mL at baseline and at 3.5 months with a daily dose of 1 mL (400 IU/mL) for 7 months
Other Names:
|
Placebo Comparator: Placebo
Placebo orally at baseline and at 3.5 months with daily placebo during 7 months
|
2 mL of placebo at baseline and at 3.5 months with a daily dose of placebo (1 mL) for 7 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of asthma exacerbations per child treated with rescue oral corticosteroids
Time Frame: 7 months
|
Group difference in the mean number of exacerbations treated with rescue oral corticosteroids/child
|
7 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Laboratory-confirmed respiratory infections
Time Frame: 7 months
|
Group difference in mean number of laboratory-confirmed respiratory infections during asthma exacerbations
|
7 months
|
Severity of asthma symptoms during asthma exacerbations
Time Frame: 7 months
|
Group difference in the mean severity of asthma symptoms documented on the 'Asthma Flare-up Diary for Young Children'
|
7 months
|
Duration of asthma symptoms during asthma exacerbations
Time Frame: 7 months
|
Group difference in the mean duration of asthma symptoms documented on the validated 'Asthma Flare-up Diary for Young Children'
|
7 months
|
Intensity of use of rescue β2-agonists during asthma exacerbations
Time Frame: 7 months
|
Group difference in the mean cumulative use of rescue β2-agonists during exacerbations documented on the validated 'Asthma Flare-up Diary for Young Children'
|
7 months
|
Parents' functional status during asthma exacerbations
Time Frame: 7 months
|
Group difference in the mean parents' functional status during exacerbation as documented on the validated 'Effect of a child's asthma flare-up on parents questionnaire'
|
7 months
|
Mean number of ED visits for asthma exacerbations
Time Frame: 7 months
|
Group difference in mean number of ED visits for asthma exacerbations
|
7 months
|
De-intensification of preventive asthma therapy
Time Frame: 7 months
|
Group difference in proportion of children with de-intensification of preventive asthma therapy
|
7 months
|
Intervention cost-effectiveness
Time Frame: 7 months
|
Cost of intervention vs. cost (family expenses and health care) of exacerbations
|
7 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hypercalciuria
Time Frame: 7 months
|
Group difference in the proportion of children with ≥1 occurrence of hypercalciuria (urinary calcium: creatinine ratio >1.38 mmol/mmol for children aged 1-<2 years, or >1.1 mmol/mmol for children aged 2-<5 years, or >0.77 mmol/mmol for children aged ≥5 years)
|
7 months
|
Hypercalcemia
Time Frame: 7 months
|
Group difference in the proportion of children with clinically significant hypercalcemia (>2.63 mmol/L)
|
7 months
|
Elevated serum 25-hydroxyvitamin D
Time Frame: 7 months
|
Group difference in the proportion of children with ≥1 occurrence of elevated serum 25OHD (greater than 250 nmol/L)
|
7 months
|
Adverse Health Events
Time Frame: 7 months
|
Group difference in the distribution of adverse health events
|
7 months
|
Gene expression
Time Frame: 3.5 months
|
Group difference in the change in gene expression levels (between baseline and 3.5 months) in blood peripherical mononuclear cells, adjusted for cell distribution estimated from lymphocyte differentiation in a subset of patients
|
3.5 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Francine M Ducharme, MD, Study Principal Investigator
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Immune System Diseases
- Lung Diseases
- Hypersensitivity, Immediate
- Bronchial Diseases
- Lung Diseases, Obstructive
- Respiratory Hypersensitivity
- Hypersensitivity
- Asthma
- Physiological Effects of Drugs
- Micronutrients
- Vitamins
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Vitamin D
- Cholecalciferol
Other Study ID Numbers
- MP-21-2018-1657
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
-
Johann Wolfgang Goethe University HospitalCompletedExercise-induced AsthmaGermany
Clinical Trials on Vitamin D
-
PfizerTerminated
-
Umeå UniversityRegion SkaneCompleted
-
Khon Kaen UniversityNot yet recruiting
-
Fundación Cardiovascular de ColombiaUniversidad Industrial de Santander; Farma de Colombia SACompletedVitamin D Deficiency | Overweight and Obesity | Overweight AdolescentsColombia
-
Nutrition Institute, SloveniaSlovenian Research Agency; Higher School of Applied Sciences (VIST); Valens Int...CompletedVitamin D DeficiencySlovenia
-
USDA, Western Human Nutrition Research CenterCompletedVitamin D DeficiencyUnited States
-
University of AarhusNot yet recruitingImmune System Diseases | Growth | Child Development | Vitamin D Supplementation
-
University Hospital, Basel, SwitzerlandCompleted
-
Cornell UniversityArogyavaram Medical CentreNot yet recruiting
-
Brigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI)Active, not recruiting